Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum vs Non-platinum Neoadjuvant Chemo in TNBC
NCT05872412Phase 2Unknown
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Pathological complete response rate at 1 year. Status: unknown.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05872412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872412.